FDA reviewing Synergy's plecanatide

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) said FDA accepted an NDA for plecanatide ( SP-304) to treat chronic idiopathic constipation (CIC). The PDUFA date is Jan. 29, 2017.

Last year, the guanylate cyclase C ( GCC; GUCY2C) agonist improved the proportion of durable overall responders in two placebo-controlled Phase III studies to treat CIC. ...